Logo image of AB.PA

AB SCIENCE SA (AB.PA) Stock Fundamental Analysis

EPA:AB - Euronext Paris - Matif - FR0010557264 - Common Stock - Currency: EUR

1.466  +0.03 (+1.95%)

Fundamental Rating

1

Taking everything into account, AB scores 1 out of 10 in our fundamental rating. AB was compared to 50 industry peers in the Pharmaceuticals industry. AB has a bad profitability rating. Also its financial health evaluation is rather negative. AB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AB had negative earnings in the past year.
AB had a negative operating cash flow in the past year.
In the past 5 years AB always reported negative net income.
In the past 5 years AB always reported negative operating cash flow.
AB.PA Yearly Net Income VS EBIT VS OCF VS FCFAB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

AB's Return On Assets of -26.29% is on the low side compared to the rest of the industry. AB is outperformed by 74.00% of its industry peers.
Industry RankSector Rank
ROA -26.29%
ROE N/A
ROIC N/A
ROA(3y)-57.37%
ROA(5y)-69.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AB.PA Yearly ROA, ROE, ROICAB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K -1.5K

1.3 Margins

AB has a Gross Margin of 76.25%. This is in the better half of the industry: AB outperforms 72.00% of its industry peers.
In the last couple of years the Gross Margin of AB has declined.
The Profit Margin and Operating Margin are not available for AB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-6.66%
AB.PA Yearly Profit, Operating, Gross MarginsAB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

AB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AB has been increased compared to 5 years ago.
Compared to 1 year ago, AB has an improved debt to assets ratio.
AB.PA Yearly Shares OutstandingAB.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
AB.PA Yearly Total Debt VS Total AssetsAB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

AB has an Altman-Z score of -18.01. This is a bad value and indicates that AB is not financially healthy and even has some risk of bankruptcy.
AB has a worse Altman-Z score (-18.01) than 78.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.01
ROIC/WACCN/A
WACC7.1%
AB.PA Yearly LT Debt VS Equity VS FCFAB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

2.3 Liquidity

AB has a Current Ratio of 0.82. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.82, AB is not doing good in the industry: 84.00% of the companies in the same industry are doing better.
AB has a Quick Ratio of 0.82. This is a bad value and indicates that AB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of AB (0.80) is worse than 64.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.8
AB.PA Yearly Current Assets VS Current LiabilitesAB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

AB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.19%, which is quite impressive.
The Revenue has grown by 39.25% in the past year. This is a very strong growth!
Measured over the past years, AB shows a very negative growth in Revenue. The Revenue has been decreasing by -10.63% on average per year.
EPS 1Y (TTM)66.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.87%
Revenue 1Y (TTM)39.25%
Revenue growth 3Y-15.06%
Revenue growth 5Y-10.63%
Sales Q2Q%25%

3.2 Future

AB is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.78% yearly.
AB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.47% yearly.
EPS Next Y-20.59%
EPS Next 2Y-5.72%
EPS Next 3Y-3.78%
EPS Next 5YN/A
Revenue Next Year37.5%
Revenue Next 2Y23.51%
Revenue Next 3Y18.47%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AB.PA Yearly Revenue VS EstimatesAB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
AB.PA Yearly EPS VS EstimatesAB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AB.PA Price Earnings VS Forward Price EarningsAB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AB.PA Per share dataAB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

AB's earnings are expected to decrease with -3.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.72%
EPS Next 3Y-3.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AB SCIENCE SA

EPA:AB (5/9/2025, 7:00:00 PM)

1.466

+0.03 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)05-13 2025-05-13
Inst Owners0.19%
Inst Owner ChangeN/A
Ins Owners35.25%
Ins Owner ChangeN/A
Market Cap84.78M
Analysts86.67
Price Target3.53 (140.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.87%
PT rev (3m)-48.47%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.02
BVpS-0.43
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.25%
FCFM N/A
ROA(3y)-57.37%
ROA(5y)-69.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-6.66%
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.69%
Cap/Sales 23.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.82
Quick Ratio 0.8
Altman-Z -18.01
F-Score3
WACC7.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)45.96%
Cap/Sales(5y)37.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.87%
EPS Next Y-20.59%
EPS Next 2Y-5.72%
EPS Next 3Y-3.78%
EPS Next 5YN/A
Revenue 1Y (TTM)39.25%
Revenue growth 3Y-15.06%
Revenue growth 5Y-10.63%
Sales Q2Q%25%
Revenue Next Year37.5%
Revenue Next 2Y23.51%
Revenue Next 3Y18.47%
Revenue Next 5YN/A
EBIT growth 1Y46.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.59%
EBIT Next 3Y-19.34%
EBIT Next 5YN/A
FCF growth 1Y75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.39%
OCF growth 3YN/A
OCF growth 5YN/A